Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apogee Takes Aim at Regeneron, Lilly as it Readies IPO","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$263.1 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics to Raise up to $263.1M in IPO","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4RR\u03b1 Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$483.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters\u2122 Option to Purchase Additional Shares for Gross Proceeds of $483 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Apogee Therapeutics

    Menu

    Apogee Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Apogee Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4RRα Antibody for the Treatment of Chronic Obstructive P...

              Details:

              APG808 is a novel subcutaneous extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.

              Lead Product(s): APG808

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: APG808

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Apogee Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters™ Option to Purchase Additional Shares for Gross Proceeds of $...

              Details:

              The company intends to use the proceeds to fund our clinical trials and manufacturing ofits APG777 program, a novel, subcutaneous monoclonal antibody with an extended half-life, targeting interleukin(IL)-13, aimed at addressing moderate-to-severe atopic dermatitis and asthma.

              Lead Product(s): APG777

              Therapeutic Area: Dermatology Product Name: APG777

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: $483.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering March 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Apogee Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

              Details:

              The net proceeds will be used in the clinical advancement of Apogee lead product APG777, which is being evaluated in Phase I clinical trial studies for the treatment of Atopic dermatitis and also including Asthma.

              Lead Product(s): APG777

              Therapeutic Area: Dermatology Product Name: APG777

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: $420.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering March 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Apogee Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermati...

              Details:

              APG777 is a novel, subcutaneous extended half-life monoclonal antibody targeting IL-13 – a critical cytokine in inflammation and a primary driver of Atopic Dermatitis and Other Inflammatory Diseases.

              Lead Product(s): APG777

              Therapeutic Area: Dermatology Product Name: APG777

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Apogee Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares

              Details:

              The net proceeds will fund company's clinical trials, including a potential Phase 2 trial, and manufacturing of its APG777, APG808, APG990 and APG222 programs, fund its preclinical studies, clinical trials.

              Lead Product(s): APG777

              Therapeutic Area: Dermatology Product Name: APG777

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: $345.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering July 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Apogee Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering

              Details:

              The net proceeds will fund company's clinical trials, including a potential Phase 2 trial, and manufacturing of its APG777, APG808, APG990 and APG222 programs, fund its preclinical studies, clinical trials.

              Lead Product(s): APG777

              Therapeutic Area: Dermatology Product Name: APG777

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: $300.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering July 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Apogee Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Therapeutics to Raise up to $263.1M in IPO

              Details:

              The net proceeds will fund company's clinical trials, including a potential Phase 2 trial, and manufacturing of its APG777, APG808, APG990 and APG222 programs, fund its preclinical studies, clinical trials.

              Lead Product(s): APG777

              Therapeutic Area: Dermatology Product Name: APG777

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: $263.1 million Upfront Cash: Undisclosed

              Deal Type: Public Offering July 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Apogee Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apogee Takes Aim at Regeneron, Lilly as it Readies IPO

              Details:

              The net proceeds will fund the company's preclinical studies, clinical trials, including a potential Phase 2 trial, and manufacturing of its APG777 program, a subcutaneous extended half-life monoclonal antibody targeting IL-13, being developed for inflammatory and immunological diseases.

              Lead Product(s): APG777

              Therapeutic Area: Dermatology Product Name: APG777

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Jefferies

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Public Offering June 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY